USP8 deubiquitinates numerous plasma membrane receptors, making this enzyme a promising target in cancer therapy to overcome chemoresistance associated with RTK stabilization (Byun et al., 2013; Islam et al., 2021). This evidence concerns the gene USP8 and cancer.